To view the Abstract, just click the link.
To request a reprint of the paper, click the link "Request Article", and send the Email
To download slides, right-click the link labeled "slides" and "Save Target As" to save the slides to your computer.
To return to the main library, just click "Back
TIMI 11 Articles
1. Nick R. Bijsterveld, MD, Ron J. G. Peters, MD, Sabina A. Murphy, MPH, Peter J. L. M. Bernink, MD, Jan G. P. Tijssen, PHD, Marc Cohen, MD, FACC for the TIMI 11B/ESSENCE Study Groups Recurrent Cardiac Ischemic Events Early After Discontinuation of Short-Term Heparin Treatment in Acute Coronary Syndromes Results From the Thrombolysis In Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events (ESSENCE) Studies (J Am Coll Cardiol Dec 17 2003;42:2083–9)
2. James A. de Lemos, MD, David A. Morrow, MD, MPH, C. Michael Gibson, MD, MS, FACC, Sabina A. Murphy, MPH, Marc S. Sabatine, MD, Nader Rifai, PHD, Carolyn H. McCabe, BS, Elliott M. Antman, MD, FACC, Christopher P. Cannon, MD, FACC, Eugene Braunwald, MD, FACC The Prognostic Value of Serum Myoglobin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Results From the TIMI 11B and TACTICS-TIMI 18 Studies Journal of the American College of Cardiology 2002 July 17;40:238–44
3. Keith A.A. Fox, MB, ChB, Elliott M. Antman, MD, Marc Cohen, MD, andF rederique Bigonzi, MD, on behalf of the ESSENCE/TIMI 11B Investigators Comparison of Enoxaparin Versus Unfractionated Heparin in Patients With Unstable Angina Pectoris/Non–STSegment Elevation Acute Myocardial Infarction Having Subsequent Percutaneous Coronary Intervention. American Journal of Cardiology Sep 1 2002;90:477–482
4. Richard C. Becker, MD, Frederick A. Spencer, MD, Michael Gibson, MD, Janet E. Rush, MD, Gerard Sanderink, PhD, Sabina A. Murphy, MPH, Steven P. Ball, RN, and Elliott M. Antman, MD, for the TIMI 11A Investigators Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non–ST-segment elevation acute coronary syndromes (Am Heart J 2002;143: 753-9.)
5. E. M. Antman, M. Cohen, C. McCabe, S. G. Goodman, S. A. Murphy and E. Braunwald for the TIMI 11B and ESSENCE Investigators Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE European Heart Journal 2002 Feb; 23: 308–314,
6. David A. Morrow, MD, Elliott M. Antman, MD, FACC, Milenko Tanasijevic, MD, Nader Rifai, PHD, James A. de Lemos, MD, Carolyn H. McCabe, BS, Christopher P. Cannon, MD, FACC, Eugene Braunwald, MD, FACC Cardiac Troponin I for Stratification of Early Outcomes and the Efficacy of Enoxaparin in Unstable Angina: A TIMI-11B Substudy Journal of the American College of Cardiology 2000 Nov;36:1812–7
7. David A. Morrow, Nader Rifai, Milenko J. Tanasijevic, Donald R. Wybenga, James A. de Lemos, and Elliott M. Antman Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy Clinical Chemistry 46:4 453–460 (2000) Apr
8. David A. Morrow, MD, Nader Rifai, PHD, Elliott M. Antman, MD, FACC, Debra L. Weiner, MD, PHD, Carolyn H. McCabe, BS, Christopher P. Cannon, MD, FACC, Eugene Braunwald, MD, FACC Serum Amyloid A Predicts Early Mortality in Acute Coronary Syndromes: A TIMI 11A Substudy Journal of the American College of Cardiology 2000 Feb;35:358–62
9. Gerardo E. Bozovich, MD, Enrique P. Gurfinkel, MD, PhD, Elliott M. Antman, MD, Carolyn H. McCabe, BS, and Branco Mautner, MD, for the TIMI 11B investigators Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time(Am Heart J 2000;140:637-42.)
10. Elliott M. Antman, MD; Marc Cohen, MD; David Radley, MS; Carolyn McCabe, BS; Janet Rush, MD; Jerome Premmereur, MD; Eugene Braunwald, MD; for the TIMI 11B (Thrombolysis In Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events) Investigators Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction TIMI 11B–ESSENCE Meta-Analysis Circulation. 1999 Oct 12;100:1602-1608.
11. Elliott M. Antman, MD; Carolyn H. McCabe, BS; Enrique P. Gurfinkel, MD; Alexander G.G. Turpie, MD; Peter J.L.M. Bernink, MD; Diana Salein, MD; Antonio Bayes de Luna, MD; Kim Fox, MD; Jean-Marc Lablanche, MD; David Radley, MS; Jerome Premmereur, MD; Eugene Braunwald, MD; for the TIMI 11B Investigators Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial (Circulation. Oct. 12 1999;100:1593-1601.)
12. DAVID A. MORROW, MD, NADER RIFAI, PHD, ELLIOTT M. ANTMAN, MD, FACC, DEBRA L. WEINER, MD, PHD, CAROLYN H. MCCABE, BS, CHRISTOPHER P. CANNON, MD, FACC, EUGENE BRAUNWALD, MD, FACC. C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy Journal of the American College of Cardiology 1998 Jun;31:1460 –5
13. ELLIOTT M. ANTMAN, MD, FACC, DAVID B. SACKS, MD, NADER RIFAI, PHD, CAROLYN H. MCCABE, BS, CHRISTOPHER P. CANNON, MD, FACC, EUGENE BRAUNWALD, MD, FACC Time to Positivity of a Rapid Bedside Assay for Cardiac-Specific Troponin T Predicts Prognosis in Acute Coronary Syndromes: A Thrombolysis in Myocardial Infarction (TIMI) 11A Substudy Journal of the American College of Cardiology 1998 Feb;31:326 –30
14. Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11A THE THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) 11A TRIAL INVESTIGATORS (J Am Coll Cardiol June 1997;29:1474–82)